


King Saud University  
**Saudi Journal of Biological Sciences**

www.ksu.edu.sa  
www.sciencedirect.com



الجمعية السعودية لعلمون الحياة  
SAUDI BIOLOGICAL SOCIETY

REVIEW

# Clinical biomarkers in sickle cell disease



Ghazi A. Damanhour<sup>a</sup>, Jummanah Jarullah<sup>a,\*</sup>, Samy Marouf<sup>b</sup>, S.I. Hindawi<sup>a</sup>,  
Gohar Mushtaq<sup>c</sup>, Mohammad A. Kamal<sup>d</sup>

<sup>a</sup> Hematology Research Lab, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia

<sup>b</sup> King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia

<sup>c</sup> Department of Biochemistry, College of Science, King Abdulaziz University, Jeddah, Saudi Arabia

<sup>d</sup> Metabolomics and Enzymology Unit, Fundamental and Applied Biology, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia

Received 3 June 2014; revised 10 September 2014; accepted 10 September 2014  
Available online 18 September 2014

**KEYWORDS**

Biomarkers;  
Polymerization;  
Sickle cell disease;  
Vaso-occlusion;  
Reticulocytes count;  
Hypercoagulability

**Abstract** Sickle cell disease (SCD) is a hereditary blood disorder caused by a single gene. Various blood and urine biomarkers have been identified in SCD which are associated with laboratory and medical history. Biomarkers have been proven helpful in identifying different interconnected disease-causing mechanisms of SCD, including hypercoagulability, hemolysis, inflammation, oxidative stress, vasculopathy, reperfusion injury and reduced vasodilatory responses in endothelium, to name just a few. However, there exists a need to establish a panel of validated blood and urine biomarkers in SCD. This paper reviews the current contribution of biochemical markers associated with clinical manifestation and identification of sub-phenotypes in SCD.


© 2014 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/3.0/>).

**Contents**

1. Introduction . . . . .	25
1.1. Biomarkers in SCD . . . . .	25
1.2. Biomarkers used for HbS polymerization . . . . .	25
1.2.1. HbF . . . . .	26
1.2.2. Co-inheritance of $\alpha$ -thalassemia . . . . .	26

\* Corresponding author at: Hematology Research Lab, King Fahd Medical Research Centre, King Abdulaziz University, P.O. Box 80216, Jeddah 21589, Saudi Arabia. Tel.: +966 (2) 6400000x25020, +966 506570449 (mobile); fax: +966(2) 6952076.

E-mail address: [jumanaj@gmail.com](mailto:jumanaj@gmail.com) (J. Jarullah).  
Peer review under responsibility of King Saud University.



1.3.	Biomarkers used for red blood cell dehydration . . . . .	26
1.4.	Biomarkers for red cell adhesion . . . . .	27
1.5.	Biomarkers for white cell adhesion . . . . .	27
1.6.	Biomarkers for inflammation. . . . .	27
1.6.1.	Total white cell count . . . . .	27
1.6.2.	C-reactive protein (CRP). . . . .	27
1.6.3.	Erythrocyte sedimentation rate (ESR) . . . . .	27
1.6.4.	Secretory phospholipase A2 (sPLA2) . . . . .	27
1.6.5.	Other inflammatory markers . . . . .	27
2.	Biomarkers for hemolysis. . . . .	27
2.1.	Hemoglobin concentration . . . . .	27
2.2.	Direct measurement of RBC survival . . . . .	27
2.3.	Reticulocyte count . . . . .	28
2.4.	Serum lactate. . . . .	28
2.5.	Haptoglobin . . . . .	28
3.	Biomarkers of hypercoagulability . . . . .	28
4.	Biomarkers for oxidative stress. . . . .	28
5.	Biomarkers for vasculopathy and endothelial dysfunction . . . . .	28
5.1.	Triglycerides . . . . .	28
5.2.	Apolipoprotein A-1 . . . . .	29
5.3.	Vascular endothelial growth factor (VEGF) . . . . .	29
5.4.	Placental growth factor (PGF). . . . .	29
5.5.	Endothelin-1 . . . . .	29
6.	Biomarkers of damage to specific organs . . . . .	29
6.1.	Bone disease . . . . .	29
6.2.	Cardiac disease . . . . .	29
6.3.	Tricuspid regurgitant jet velocity (TRV). . . . .	29
6.4.	NT-pro brain natriuretic peptide (NT-proBNP) . . . . .	29
6.5.	Cardiac troponin I . . . . .	29
6.6.	Hyposplenism . . . . .	29
6.7.	Pitted RBC counts . . . . .	29
6.8.	HJBs by flow cytometry . . . . .	29
6.9.	Renal dysfunction . . . . .	29
6.10.	Pulmonary dysfunction . . . . .	30
7.	Conclusion . . . . .	30
	References . . . . .	30

## 1. Introduction

Sickle cell disease (SCD) or sickle cell anemia (SCA) is an inherited disorder of hemoglobin (Hb) caused by substitution of a single nucleotide from thymine to adenine (GAG → GTG) in the β-chain of hemoglobin resulting in amino acid valine instead of glutamic acid (Rees et al., 2010). This point mutation is responsible for alteration in the properties of the hemoglobin tetramer, with a tendency to polymerize in the deoxygenated state (Ballas, 2002), altering normal, flexible biconcave shaped red blood cells (RBCs) into stiff, rigid, sickle cell. The rate of polymerization of Sickle cell hemoglobin (HbS) is directly related to fundamental pathophysiology of hemolytic anemia and vaso-occlusion (Samuel et al., 1990).

### 1.1. Biomarkers in SCD

The Biomarkers Definitions Working Group has defined a “biomarker” as a “characteristic that is objectively measured and evaluated as an indicator of normal biological or pathogenic processes, or pharmacological responses to a therapeutic intervention” (Biomarkers Definitions Working Group, 2001).

There is high variability in terms of severity of SCD. Different major complications of SCD such as acute chest syndrome (Vichinsky et al., 2000), cerebrovascular disease (Ohene-Frempong et al., 1998), kidney failure (Scheinman, 2009) and early deaths (Platt et al., 1994) lead to variability in biomarkers.

Meaningful markers therefore have prime importance in the management of this disease. In this review, we will focus on the analysis of body fluids and tissues that have prime importance in the management of SCD. DNA markers (Steinberg and Adewoye, 2006) and imaging biomarkers will not be discussed in this review although they have been shown to be beneficial in the management of SCD (Adams et al., 1998).

### 1.2. Biomarkers used for HbS polymerization

Polymerization of the deoxygenated HbS is the leading phenomenon contributing to SCD related medical problems. The polymerization initiation rate is directly proportional to quantity of deoxygenated HbS within the RBC. Currently such biomarkers which can directly measure HbS polymerization

Download English Version:

<https://daneshyari.com/en/article/4406355>

Download Persian Version:

<https://daneshyari.com/article/4406355>

[Daneshyari.com](https://daneshyari.com)